Klavs F. Jensen Net Worth

The estimated Net Worth of Klavs F. Jensen is at least $157 mil dollars as of 25 May 2022. Klavs Jensen owns over 14,326 units of SQZ Biotechnologies Co stock worth over $157,434 and over the last 4 years Klavs sold SQZ stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Klavs Jensen SQZ stock SEC Form 4 insiders trading

Klavs has made over 1 trades of the SQZ Biotechnologies Co stock since 2022, according to the Form 4 filled with the SEC. Most recently Klavs bought 14,326 units of SQZ stock worth $50,428 on 25 May 2022.

The largest trade Klavs's ever made was buying 14,326 units of SQZ Biotechnologies Co stock on 25 May 2022 worth over $50,428. On average, Klavs trades about 2,388 units every 0 days since 2020. As of 25 May 2022 Klavs still owns at least 353,309 units of SQZ Biotechnologies Co stock.

You can see the complete history of Klavs Jensen stock trades at the bottom of the page.

What's Klavs Jensen's mailing address?

Klavs's mailing address filed with the SEC is 200 ARSENAL YARDS BLVD, SUITE 210, , WATERTOWN, MA, 02472.

Insiders trading at SQZ Biotechnologies Co

Over the last 4 years, insiders at SQZ Biotechnologies Co have traded over $3,939 worth of SQZ Biotechnologies Co stock and bought 2,233,026 units worth $35,530,795 . The most active insiders traders include Holdings (Private) Ltd Temasek, Public Equities, L.P.Minne ..., eAmy W Schulman. On average, SQZ Biotechnologies Co executives and independent directors trade stock every 50 days with the average trade being worth of $78,593. The most recent stock trade was executed by Richard Capasso on 15 August 2022, trading 1,183 units of SQZ stock currently worth $3,939.

What does SQZ Biotechnologies Co do?

Complete history of Klavs Jensen stock trades at SQZ Biotechnologies Co

SQZ Biotechnologies Co executives and stock owners

SQZ Biotechnologies Co executives and other stock owners filed with the SEC include:

• Dr. Armon R. Sharei Ph.D.,
  Co-Founder, Pres, CEO, Interim Principal Financial Officer & Director
• Teri Loxam,
  Consultant & Advisor
• Dr. Howard Bernstein M.D., Ph.D.,
  Chief Scientific Officer
• Lawrence J. Knopf,
  Gen. Counsel & Sec.
• Micah Zajic,
  Chief Bus. Officer
• Ipsita Roymoulik Ph.D.,
  Sr. VP of CMC & QUALITY
• Dr. Marshelle Smith Warren M.D.,
  Chief Medical Officer
• David First,
  Chief People Officer
• Dr. Howard Bernstein,
  Chief Scientific Officer
• Richard V. Capasso CPA,
  Chief Accounting Officer
• Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
  Co-Founder & Member of Scientific Advisory Board
• Micah Zajic,
  Chief Financial Officer
• Howard Phd Md Bernstein,
  Interim Chief Executive Office
• Holdings (Private) Ltd Temasek,
  10% owner
• Oliver Rosen,
  Chief Medical Officer
• Paul Bolno,
  Director
• Sapna Srivastava,
  Director
• Teri Loxam,
  Chief Financial Officer
• Pushkal Garg,
  Director
• Klavs F. Jensen,
  Director
• International Group, Inc. A...,
  10% owner
• Marc Elia,
  Director
• David First,
  Chief People Officer
• Armon Sharei,
  President and CEO
• Amy W Schulman,
  Director
• Marc Schegerin,
  Director
• Lawrence J Knopf,
  General Counsel
• Eric Moessinger,
  Director
• Schulman, As Trustee The Ar...,
  10% owner
• Public Equities, L.P.Minne ...,
  
• Management Co. Vii, L.L.C.P...,
  
• Bernard Coulie,
  Director
• Patrick V.J.J. Vink,
  Director
• Richard Capasso,
  See Remarks
• Marshelle Smith Warren,
  Chief Medical Officer